Transglutaminase 2 serves as a pathogenic hub gene of KRAS mutant colon cancer based on integrated analysis

Table 1 Clinicopathological characteristic of colon cancer tissue microarray

Characteristic		All patients (n = 90)
Age, mean ± SD		64.11 ± 13.17
Gender, n (%)	Female	46 (51.11)
	Male	44 (48.89)
Histologic grade, n (%)	Grade II	57 (63.33)
	Grade III	33 (36.67)
Maximum tumor diameter, median (Q1, Q3)		5.40 (4.00, 7.00)
Tumor location, n (%)	Right colon	42 (46.67)
	Left colon	41 (45.56)
	Unknown	7 (7.78)
Lympho-vascular invasion, n (%)	No	60 (66.67)
	Yes	30 (33.33)
Perineural invasion, n (%)	No	74 (82.22)
	Yes	16 (17.78)
Pathologic T stage, n (%)	T2	9 (10.00)
	T3	31 (34.44)
	T4a	41 (45.56)
	T4b	9 (10.00)
Pathologic N stage, n (%)	N0	56 (62.22)
	N1	18 (20.00)
	N2	16 (17.78)
Clinical M stage, n (%)	M0	86 (95.56)
	M1	4 (4.44)
Disease stage, n (%)	I	9 (10.00)
	II	45 (50.00)
	III	32 (35.56)
	IV	4 (4.44)
CD8 positive rate, n (%)	< 5%	60 (66.67)
	≥ 5%	30 (33.33)
PD-L1 positive rate, n (%)	< 5%	63 (70.00)
	≥ 5%	27 (30.00)
PD1 positive rate, n (%)	< 5%	66 (73.33)
	≥ 5%	24 (26.67)
KRAS mutant status, n (%)	Mutant	28 (31.11)
	Wild type	62 (68.89)

PD-L1: Programmed death ligand 1; PD1: Programmed cell death 1.